The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
HGF-MET inhibitors and potential sites of action. Abbreviations: HGF,... | Download Scientific Diagram
Trends in the development of MET inhibitors for hepatocellular carcinoma | Future Oncology
Glumetinib (SCC244) | 99.87%(HPLC) | In Stock | c-Met inhibitor
Tivantinib (ARQ 197) | 99.65%(HPLC) | In Stock | c-Met inhibitor
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition | SpringerLink
Frontiers | Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
cに応じられた阻害 | c-Met Inhibition
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
c-Met inhibitor - Wikipedia
Molecules | Free Full-Text | Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors
c-Met inhibitor - Wikipedia
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer | Science Translational Medicine
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
AMG-458 is a Selective and Orally Bioavailable c-Met Inhibitor - Network of Cancer Research
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced NSCLC
Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways - ScienceDirect
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine
